Potential of Chimeric Antigen Receptor‐Engineered Mesenchymal Stem Cell (CAR‐MSC) Therapy in the Treatment of Pre‐Eclampsia

BACKGROUND: Chimeric antigen receptor (CAR) is a receptor engineered to engraft defined specificity onto immune effector cells, usually T cells, and enhance cellular function. Currently, the anticancer effects of CAR-engineered T cells, macrophages, and NK cells are being intensively explored. Pre-eclampsia (PE) is a pregnancy-specific disease with complex pathogenesis, and no effective treatment exists other than delivery. Placental dysfunction is a major contributing factor; the abnormal placenta releases factors into the maternal bloodstream, leading to systemic inflammation and widespread endothelial dysfunction. OBJECTIVE: This review comprehensively assesses the therapeutic prospects of CAR-engineered mesenchymal stem cell (CAR-MSC) therapies in addressing the pathophysiological mechanisms of PE, while outlining future directions for CAR-MSC integrated treatment strategies. CONCLUSION AND PROSPECTS: Although non-tumor research based on CAR technology is still in its early stages, in-depth investigation into CAR-MSCs may offer novel insights and perspectives for the treatment of PE by modulating placental immune function and enhancing placental repair. Given that pregnant women constitute a special population, safety considerations must be fully prioritized in future research.